PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Net income growth above 1.5x AVXL's 10.05%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-0.50%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
15.92%
Deferred tax of 15.92% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
0.65%
SBC growth while AVXL is negative at -17.58%. John Neff would see competitor possibly controlling share issuance more tightly.
-31.26%
Negative yoy working capital usage while AVXL is 563.46%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
AP growth well above AVXL's 107.94%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-40.45%
Both reduce yoy usage, with AVXL at -50.24%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-15.92%
Both negative yoy, with AVXL at -99.99%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
32.67%
Operating cash flow growth 1.25-1.5x AVXL's 23.56%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
100.00%
CapEx growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Both yoy lines negative, with AVXL at -86.08%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.